
Immaculada Margarit y Ros

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/906134/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Group B Streptococcus chimeric capsular polysaccharides as novel multivalent vaccine candidates. Glycoconjugate Journal, 2021, 38, 447-457.	2.7	5
2	Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection. Scientific Reports, 2021, 11, 21384.	3.3	2
3	Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4–6 Years After a First Dose: Results From a Phase 2 Trial. Clinical Infectious Diseases, 2020, 70, 2570-2579.	5.8	18
4	Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial. Vaccine, 2020, 38, 6930-6940.	3.8	34
5	Novel Multiplex Immunoassays for Quantification of IgG against Group B <i>Streptococcus</i> Capsular Polysaccharides in Human Sera. MSphere, 2019, 4, .	2.9	4
6	The <i>Streptococcus agalactiae</i> complement interfering protein combines multiple complementâ€inhibitory mechanisms by interacting with both C4 and C3 ligands. FASEB Journal, 2019, 33, 4448-4457.	0.5	4
7	Protective effect of Group B Streptococcus type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models. Scientific Reports, 2018, 8, 2593.	3.3	18
8	Fighting Antibiotic-Resistant Klebsiella pneumoniae with "Sweet―Immune Targets. MBio, 2018, 9, .	4.1	14
9	Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women. Journal of Infection, 2018, 76, 449-456.	3.3	22
10	Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine, 2017, 35, 361-368.	3.8	96
11	Contribution of pilus type 2b to invasive disease caused by a Streptococcus agalactiae ST-17 strain. BMC Microbiology, 2017, 17, 148.	3.3	22
12	Immune Response to Invasive Group B <i>Streptococcus</i> Disease in Adults. Emerging Infectious Diseases, 2016, 22, 1877-1883.	4.3	18
13	Genomic Analysis Reveals Multi-Drug Resistance Clusters in Group B Streptococcus CC17 Hypervirulent Isolates Causing Neonatal Invasive Disease in Southern Mainland China. Frontiers in Microbiology, 2016, 7, 1265.	3.5	40
14	The Protective Value of Maternal Group B <i>Streptococcus</i> Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera. Clinical Infectious Diseases, 2016, 63, 746-753.	5.8	53
15	The Group BStreptococcus–Secreted Protein CIP Interacts with C4, Preventing C3b Deposition via the Lectin and Classical Complement Pathways. Journal of Immunology, 2016, 196, 385-394.	0.8	15
16	Group B streptococcal infections in the newborn infant and the potential value of maternal vaccination. Expert Review of Anti-Infective Therapy, 2015, 13, 1387-1399.	4.4	28
17	Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline. Nature Communications, 2014, 5, 4544.	12.8	208
18	Structure of the Type IX Group B Streptococcus Capsular Polysaccharide and Its Evolutionary Relationship with Types V and VII. Journal of Biological Chemistry, 2014, 289, 23437-23448.	3.4	48

#	Article	IF	CITATIONS
19	A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus. Journal of Immunological Methods, 2012, 378, 11-19.	1.4	22
20	Genomic organization, structure, regulation and pathogenic role of pilus constituents in major pathogenic Streptococci and Enterococci. International Journal of Medical Microbiology, 2011, 301, 240-251.	3.6	64
21	Capturing hostâ€pathogen interactions by protein microarrays: identification of novel streptococcal proteins binding to human fibronectin, fibrinogen, and C4BP. FASEB Journal, 2009, 23, 3100-3112.	0.5	47
22	Preventing Bacterial Infections with Pilus-Based Vaccines: the Group B Streptococcus Paradigm. Journal of Infectious Diseases, 2009, 199, 108-115.	4.0	201
23	Identification of novel genomic islands coding for antigenic pilus-like structures inStreptococcus agalactiae. Molecular Microbiology, 2006, 61, 126-141.	2.5	190
24	Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen. Science, 2005, 309, 148-150.	12.6	497